ClinicalTrials.gg
TerminatedNCT04764448ESTRELLAUpdated Apr 7, 2026Results posted

A Study of Belcesiran in Patients With AATLD

A Phase 2 interventional study of Belcesiran and Placebo in Alpha 1-Antitrypsin Deficiency, sponsored by Dicerna Pharmaceuticals, Inc., a Novo Nordisk company. Terminated at 23 sites in 14 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-04-07.

Sponsored by Dicerna Pharmaceuticals, Inc., a Novo Nordisk company (part of Novo Nordisk A/S) · Phase 2, Interventional, and Other

How we know

Why this study was terminated
Development project was discontinued

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 81 studies in alpha 1-Antitrypsin Deficiency with a site in United States — 17 open to participants now, 22 under way, 5 of them phase 3. alpha 1-Antitrypsin Deficiency · United States.

Enrollment
39th of 55
16 · median 30
Started
2021
with 1 other
Phase 2
20 of 81
none open now
Registered
62nd of 81
by date

Among the 81 studies in alpha 1-Antitrypsin Deficiency with a site in United States, this one is the 39th largest by enrollment of the 55 interventional ones that give a count, is one of 2 that started in 2021, is one of 20 in phase 2, and was the 62nd registered.

alpha 1-Antitrypsin Deficiency

142 studies on the registry are indexed under alpha 1-Antitrypsin Deficiency; 32 are open to participants now.

Browse alpha 1-Antitrypsin Deficiency studies →

Open to participants now

17 of the 81 studies in alpha 1-Antitrypsin Deficiency with a site in United States are open now. Recruiting first, the newest first:

12 more — sign in →

All 17 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 24 alpha 1-Antitrypsin Deficiency studies recruiting now, 11 (46%) set no upper age limit and 10 (42%) stop at 75 or younger; 4 take children under 18; 5 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 81 studies in alpha 1-Antitrypsin Deficiency with a site in United States, or all of them as a file.
02

Study summary

This is a multiple dose, randomized, placebo-controlled, double-blind study of belcesiran to evaluate the safety, tolerability, PK, and PD in adult patients with PiZZ AATD-associated liver disease (AATLD).

The study will be conducted in 3 separate cohorts. A total of up to 16 participants may be enrolled in Cohort 1 and 2. A total number of 30 subjects will be enrolled in cohort 3. The 3 cohorts are differentiated by the duration of the treatment period, the number of doses administered, and the timing of the second liver biopsy.

Read the detailed description

AATD-associated liver disease is a progressive condition resulting in liver fibrosis, cirrhosis, and in some cases hepatocellular carcinoma. The lack of functional alpha-1 antitrypsin (AAT) in individuals with the PiZZ genotype, in conjunction with other precipitating factors, can lead to unchecked activity of neutrophil elastases in the alveoli; causing emphysema and chronic obstructive pulmonary disease (COPD). This loss-of-function mechanism may be addressed by use of intravenous augmentation therapy, which aims to substitute the missing AAT by infusing alpha-1 proteinase inhibitor (A1PI), purified from pooled human plasma.

While augmentation therapy can address the loss of AAT in the lung, no treatment exists for the associated liver disease.

Given the severity of the disease, with approximately 10% of affected patients developing liver cirrhosis and a subgroup of those patients in need of liver transplantation, and the lack of an effective treatment that addresses the toxic hepatic "gain-of-function" mechanism, there is an urgent unmet medical need to develop a therapy that can help this particular patient population.

03

Conditions studied

  • Alpha 1-Antitrypsin Deficiency
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 to 75 years, inclusive, at the time of consent.
  • Documented diagnosis of PiZZ-type alpha-1 antitrypsin deficiency, confirmed by genotyping. Historical genotyping data may be used, if available.
  • AATD-associated liver disease documented by liver at Screening.
  • Consent to undergo paired liver biopsies.
  • Lung, renal and liver function within acceptable limits
  • Capable of giving signed , which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.

Exclusion criteria

Exclusion Criteria:

  • History of chronic liver disease other than non-alcoholic fatty liver disease from any cause other than PiZZ-type alpha-1 antitrypsin deficiency.
  • Score B or C.
  • History of one single severe exacerbation of underlying lung disease in the year prior to randomization.
  • History of respiratory infections (including pneumonia and lower respiratory tract infections), as determined by the Investigator, in the 3 months prior to screening
  • Use of an RNAi drug at any time.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Belcesiran Cohort 1

    Drug: Belcesiran

  • Placebo comparator
    Placebo Cohort 1

    Other: Placebo

  • Experimental
    Belcesiran Cohort 2

    Drug: Belcesiran

  • Placebo comparator
    Placebo Cohort 2

    Other: Placebo

  • Experimental
    Belcesiran Cohort 3

    Drug: Belcesiran

  • Placebo comparator
    Placebo Cohort 3

    Other: Placebo

Interventions

  • Administered multiple fixed doses of belcesiran by subcutaneous (sc) injection for 24 weeks. Extension offered to participants.

  • OtherPlacebo

    Comparator: Placebo Cohort 1 Administered sterile normal saline (0.9% NaCl) matching volume of belcesiran by subcutaneous (sc) injection for 24 weeks. Extension offered to participants.

  • Administered multiple fixed doses of belcesiran by subcutaneous (sc) injection for 48 weeks. Extension offered to participants.

  • OtherPlacebo

    Administered sterile normal saline (0.9% NaCl) matching volumes of belcesiran by subcutaneous (sc) injection for 48 weeks. Extension offered to participants.

  • Administered multiple fixed doses of belcesiran by subcutaneous (sc) injection for 96 weeks.

  • OtherPlacebo

    Administered sterile normal saline (0.9% NaCl) matching volumes of belcesiran by subcutaneous (sc) injection for 96 weeks.

06

What researchers measure

Primary outcomes

  1. Number of Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    Number of TEAEs and SAEs is presented. An adverse event (AE) was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. AEs were defined as TEAEs if they had a start date on or after the administration of study drug during the treatment period, or if they occurred prior to the administration of study drug and worsened in severity/grade or relationship to the study intervention after the administration of study intervention during the treatment period. A SAE was defined as any untoward medical occurrence that, at any dose: a) resulted in death, b) is life-threatening, c) required inpatient hospitalization or prolongation of existing hospitalization, d) resulted in persistent disability/incapacity, e) was a congenital anomaly/birth defect.

    Time frame: Up to 2.6 years

  2. Number of Participants With TEAEs and SAEs

    Number of participants with TEAEs and SAEs is presented. An AE was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. AEs were defined as TEAEs if they had a start date on or after the administration of study drug during the treatment period, or if they occurred prior to the administration of study drug and worsened in severity/grade or relationship to the study intervention after the administration of study intervention during the treatment period. A SAE was defined as any untoward medical occurrence that, at any dose: a) resulted in death, b) is life-threatening, c) required inpatient hospitalization or prolongation of existing hospitalization, d) resulted in persistent disability/incapacity, e) was a congenital anomaly/birth defect.

    Time frame: Up to 2.6 years

  3. Change From Baseline in Pulmonary Function Tests (PFTs): Forced Vital Capacity (FVC)

    Change in FVC from baseline (Day 1) to week 96 is presented. FVC is the maximal volume of air exhaled with maximally forced effort from a maximal inspiration, that is, VC performed with a maximally forced expiratory effort.

    Time frame: Baseline (Day 1), week 96

  4. Change From Baseline in PFT: Forced Expiratory Volume in One Second (FEV1)

    Change in FEV1 from baseline (Day 1) to week 96 is presented. FEV1 is the maximal volume of air exhaled in the first second of a forced expiration from a position of full inspiration.

    Time frame: Baseline (Day 1), week 96

  5. Change From Baseline in PFT: FEV1/FVC Ratio

    Change in FEV1/FVC ratio from baseline (Day 1) to week 96 is presented. FEV1 is the maximal volume of air exhaled in the first second of a forced expiration from a position of full inspiration. FVC is the maximal volume of air exhaled with maximally forced effort from a maximal inspiration, that is, VC performed with a maximally forced expiratory effort.

    Time frame: Baseline (Day 1), week 96

  6. Change From Baseline in PFT: Diffusing Capacity of the Lungs for Carbon Monoxide (DLCO)

    Change in DLCO from baseline (Day 1) to week 96 is presented. DLCO is a measure of the quantity of carbon monoxide (CO) transferred per minute from alveolar gas to red blood cells (specifically hemoglobin) in pulmonary capillaries. It is expressed as millimoles per minute per kilopascal (mmol/min/kPa).

    Time frame: Baseline (Day 1), week 96

  7. Change From Baseline in 12 -Lead Electrochardiograms (ECGs): Mean Heart Rate

    Change from baseline (Day 1) to week 96 in mean heart rate is presented.

    Time frame: Baseline (Day 1), week 96

  8. Change From Baseline in 12 -Lead ECGs: Mean Ventricular Rate

    Change from baseline (Day 1) to week 96 in mean ventricular rate is presented.

    Time frame: Baseline (Day 1), week 96

  9. Change From Baseline in 12 -Lead ECGs: PR Interval, QRS Interval, QT Interval, QTcF Interval and RR Interval

    Change from baseline (Day 1) to week 96 in PR interval, QRS interval, QT interval, QTcF interval and RR interval is presented.

    Time frame: Baseline (Day 1), week 96

  10. Number of Participants With Physical Examination Findings

    Number of participants with physical examination findings at week 96 is presented. The data is presented under categories:a) Normal, b) Abnormal, not clinically significant, c) Abnormal, clinically significant.

    Time frame: At week 96

  11. Change From Baseline in Vital Signs: Diastolic Blood Pressure and Systolic Blood Pressure

    Change from baseline (Day 1) to week 96 in diastolic blood pressure and systolic blood pressure is presented.

    Time frame: Baseline (Day 1), week 96

  12. Change From Baseline in Vital Signs: Heart Rate

    Change from baseline (Day 1) to week 96 in heart rate is presented.

    Time frame: Baseline (Day 1), week 96

  13. Vital Signs: Height at Baseline

    Height at baseline is presented.

    Time frame: Baseline (Day 1)

  14. Change From Baseline in Vital Signs: Respiratory Rate

    Change from baseline (Day 1) to week 96 in respiratory rate is presented.

    Time frame: Baseline (Day 1), week 96

  15. Change From Baseline in Vital Signs: Temperature

    Change from baseline (Day 1) to week 96 in temperature is presented.

    Time frame: Baseline (Day 1), week 96

  16. Change From Baseline in Vital Signs: Weight

    Change from baseline (Day 1) to week 96 in weight is presented.

    Time frame: Baseline (Day 1), week 96

  17. Change in Clinical Laboratory Tests: Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase, Creatine Kinase, Glutamate Dehydrogenase, Lactate Dehydrogenase, Biomarker Creatine Kinase (M30) and Biomarker Creatine Kinase (M65)

    Change from baseline (Day 1) to week 96 in alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, creatine kinase, glutamate dehydrogenase, lactate dehydrogenase, biomarker creatine kinase (M30) and biomarker creatine kinase (M65) is presented.

    Time frame: Baseline (Day 1), week 96

  18. Change From Baseline in Clinical Laboratory Tests: Albumin, Apolipoprotein A1, Protein, Biomarker Haptoglobin

    Change from baseline (Day 1) to week 96 in albumin, apolipoprotein A1, protein and biomarker haptoglobin is presented.

    Time frame: Baseline (Day 1), week 96

  19. Change From Baseline in Clinical Laboratory Tests: Bilirubin, Creatinine and Direct Bilirubin

    Change from baseline (Day 1) to week 96 in bilirubin, creatinine and direct bilirubin is presented.

    Time frame: Baseline (Day 1), week 96

  20. Change From Baseline in Clinical Laboratory Tests: Chloride, Cholesterol, Glucose, Potassium, Sodium, Triglycerides and Urea Nitrogen

    Change from baseline (Day 1) to week 96 in chloride, cholesterol, glucose, potassium, sodium, triglycerides and urea nitrogen is presented.

    Time frame: Baseline (Day 1), week 96

  21. Change From Baseline in Clinical Laboratory Tests: Gamma Glutamyl Transferase

    Change from baseline (Day 1) to week 96 in gamma glutamyl transferase is presented.

    Time frame: Baseline (Day 1), week 96

  22. Change From Baseline in Clinical Laboratory Tests: Basophils, Eosinophils, Leucocytes, Lymphocytes, Monocytes, Neutrophils and Platelets

    Change from baseline (Day 1) to week 96 in basophils, eosinophils, leucocytes, lymphocytes, monocytes, neutrophils and platelets is presented.

    Time frame: Baseline (Day 1), week 96

  23. Change From Baseline in Clinical Laboratory Tests: Basophils/Leucocytes

    Change from baseline (Day 1) to week 96 in basophils/leucocytes is presented.

    Time frame: Baseline (Day 1), week 96

  24. Change From Baseline in Clinical Laboratory Tests: Eosinophils/Leucocytes

    Change from baseline (Day 1) to week 96 in eosinophils/leucocytes is presented.

    Time frame: Baseline (Day 1), week 96

  25. Change From Baseline in Clinical Laboratory Tests: Haematocrit

    Change from baseline (Day 1) to week 96 in haematocrit is presented.

    Time frame: Baseline (Day 1), week 96

  26. Change From Baseline in Clinical Laboratory Tests: Lymphocytes/Leucocytes

    Change from baseline (Day 1) to week 96 in lymphocytes/leucocytes is presented.

    Time frame: Baseline (Day 1), week 96

  27. Change From Baseline in Clinical Laboratory Tests: Monocytes/Leucocytes

    Change from baseline (Day 1) to week 96 in monocytes/leucocytes is presented.

    Time frame: Baseline (Day 1), week 96

  28. Change From Baseline in Clinical Laboratory Tests: Neutrophils/Leucocytes

    Change from baseline (Day 1) to week 96 in neutrophils/leucocytes is presented.

    Time frame: Baseline (Day 1), week 96

  29. Change From Baseline in Clinical Laboratory Tests: Reticulocytes/Erythrocytes

    Change from baseline (Day 1) to week 96 in reticulocytes/erythrocytes is presented.

    Time frame: Baseline (Day 1), week 96

  30. Change From Baseline in Clinical Laboratory Tests: Erythrocyte Mean Corpuscular Haemoglobin Concentration and Haemoglobin

    Change from baseline (Day 1) to week 96 in erythrocyte mean corpuscular haemoglobin concentration and haemoglobin is presented.

    Time frame: Baseline (Day 1), week 96

  31. Change From Baseline in Clinical Laboratory Tests: Erythrocyte Mean Corpuscular Haemoglobin

    Change from baseline (Day 1) to week 96 in erythrocyte mean corpuscular haemoglobin is presented.

    Time frame: Baseline (Day 1), week 96

  32. Change From Baseline in Clinical Laboratory Tests: Erythrocyte Mean Corpuscular Volume

    Change from baseline (Day 1) to week 96 in erythrocyte mean corpuscular volume is presented.

    Time frame: Baseline (Day 1), week 96

  33. Change From Baseline in Clinical Laboratory Tests: Erythrocytes

    Change from baseline (Day 1) to week 96 in erythrocytes is presented.

    Time frame: Baseline (Day 1), week 96

  34. Change From Baseline in Clinical Laboratory Tests: Specific Gravity

    Change from baseline (Day 1) to week 96 in specific gravity is reported.

    Time frame: Baseline (Day 1), week 96

  35. Change From Baseline in Clinical Laboratory Tests: Urine Erythrocytes and Urine Leucocytes

    Change from baseline (Day 1) to week 96 in urine erythrocytes and urine leucocytes is presented.

    Time frame: Baseline (Day 1), week 96

  36. Change From Baseline in Clinical Laboratory Tests: Potential of Hydrogen (pH)

    Change from baseline (Day 1) to week 96 in pH is presented.

    Time frame: Baseline (Day 1), week 96

  37. Change From Baseline in Clinical Laboratory Tests: Activated Partial Thromboplastin Time and Prothrombin Time

    Change from baseline (Day 1) to week 96 in activated partial thromboplastin time and prothrombin time is presented.

    Time frame: Baseline (Day 1), week 96

  38. Change From Baseline in Clinical Laboratory Tests: Prothrombin International Normalized Ratio

    Change from baseline (Day 1) to week 96 in prothrombin international normalized ratio is presented.

    Time frame: Baseline (Day 1), week 96

  39. Change in Clinical Laboratory Tests: Alpha Fetoprotein, Biomarker Hyaluronic Acid, Biomarker Matrix Metalloproteinase 9, Biomarker Procollagen 3 N-Terminal Propeptide, Biomarker Tissue Inhibitor of Metalloproteinase 1, Complement C3a and Complement C5a

    Change from baseline (Day 1) to week 96 in alpha fetoprotein, biomarker hyaluronic acid, biomarker matrix metalloproteinase 9, biomarker procollagen 3 N-Terminal propeptide, biomarker tissue inhibitor of metalloproteinase 1, complement C3a and complement C5a is presented.

    Time frame: Baseline (Day 1), week 96

  40. Change From Baseline in Clinical Laboratory Tests: C-Reactive Protein

    Change from baseline (Day 1) to week 96 in C-reactive protein is presented.

    Time frame: Baseline (Day 1), week 96

  41. Change From Baseline in Clinical Laboratory Tests: Complement Bb

    Change from baseline (Day 1) to week 96 in complement Bb is presented.

    Time frame: Baseline (Day 1), week 96

  42. Change From Baseline in Clinical Laboratory Tests: Complement Total (CH50)

    Change from baseline (Day 1) to week 96 in CH50 is presented.

    Time frame: Baseline (Day 1), week 96

  43. Cohort 1: Change From Baseline in Serum Alpha-1 Antitrypsin (AAT) Protein Concentrations

    Change from baseline (Day 1) to week 24 in serum AAT protein concentrations in Cohort 1 is presented.

    Time frame: Baseline (Day 1), week 24

  44. Cohort 2: Change From Baseline in Serum AAT Protein Concentrations

    Change from baseline (Day 1) to week 48 in serum AAT protein concentrations in Cohort 2 is presented.

    Time frame: Baseline (Day 1), week 48

Secondary outcomes

  1. Change From Baseline in Liver Fibrosis Ishak Score

    Change from Baseline up until week 48 in liver fibrosis based on Ishak score is presented. The Ishak staging system for liver fibrosis is a 1995 update to the algorithm initially developed by De Groote et al. Ishak scores range from 0 (no fibrosis) to 6 (cirrhosis) which are as follows: 0-no fibrosis, 1-fibrous expansion of some portal areas, with or without short fibrous septa, 2-Fibrous expansion of most portal areas, with or without short fibrous septa, 3-Fibrous expansion of most portal areas with occasional portal-to-portal bridging, 4-Fibrous expansion of portal areas with marked bridging (portal to portal as well as portal to central), 5-Marked bridging (portal-portal and/or portal-central) with occasional nodules (incomplete cirrhosis), 6-Cirrhosis, probable or definite.

    Time frame: Baseline (Day 1), week 48

07

Results

Posted Dec 31, 2024

Participant flow

The trial was conducted at 8 sites in 8 countries. The number of sites that randomised participants are as follows: Australia (1), Belgium (1), Germany (1), Netherlands (1), New zealand (1), Portugal (1), Spain (1) and United states of America (1).

Participant flow — Overall Study
MilestonePooled PlaceboCohort 1: BelcesiranCohort 2: Belcesiran
Started556
Safety population556
Completed000
Not completed556
Withdrew: Study terminated by sponsor225
Withdrew: Withdrawal by subject331

Outcome measures

PrimaryNumber of Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

Number of TEAEs and SAEs is presented. An adverse event (AE) was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. AEs were defined as TEAEs if they had a start date on or after the administration of study drug during the treatment period, or if they occurred prior to the administration of study drug and worsened in severity/grade or relationship to the study intervention after the administration of study intervention during the treatment period. A SAE was defined as any untoward medical occurrence that, at any dose: a) resulted in death, b) is life-threatening, c) required inpatient hospitalization or prolongation of existing hospitalization, d) resulted in persistent disability/incapacity, e) was a congenital anomaly/birth defect.

Time frame:
Up to 2.6 years
Reported as:
Number · Events
Number of Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
EventsPooled PlaceboCohort 1: BelcesiranCohort 2: Belcesiran
TEAE278043
SAE075
PrimaryNumber of Participants With TEAEs and SAEs

Number of participants with TEAEs and SAEs is presented. An AE was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. AEs were defined as TEAEs if they had a start date on or after the administration of study drug during the treatment period, or if they occurred prior to the administration of study drug and worsened in severity/grade or relationship to the study intervention after the administration of study intervention during the treatment period. A SAE was defined as any untoward medical occurrence that, at any dose: a) resulted in death, b) is life-threatening, c) required inpatient hospitalization or prolongation of existing hospitalization, d) resulted in persistent disability/incapacity, e) was a congenital anomaly/birth defect.

Time frame:
Up to 2.6 years
Reported as:
Count of participants · Participants
Number of Participants With TEAEs and SAEs
ParticipantsPooled PlaceboCohort 1: BelcesiranCohort 2: Belcesiran
TEAE555
SAE022
PrimaryChange From Baseline in Pulmonary Function Tests (PFTs): Forced Vital Capacity (FVC)

Change in FVC from baseline (Day 1) to week 96 is presented. FVC is the maximal volume of air exhaled with maximally forced effort from a maximal inspiration, that is, VC performed with a maximally forced expiratory effort.

Time frame:
Baseline (Day 1), week 96
Reported as:
Mean · Liters (L)
Change From Baseline in Pulmonary Function Tests (PFTs): Forced Vital Capacity (FVC)
Liters (L)Pooled PlaceboCohort 1: BelcesiranCohort 2: Belcesiran
Change From Baseline in Pulmonary Function Tests (PFTs): Forced Vital Capacity (FVC)-0.410-0.250 ± 0.0424—
PrimaryChange From Baseline in PFT: Forced Expiratory Volume in One Second (FEV1)

Change in FEV1 from baseline (Day 1) to week 96 is presented. FEV1 is the maximal volume of air exhaled in the first second of a forced expiration from a position of full inspiration.

Time frame:
Baseline (Day 1), week 96
Reported as:
Mean · L
Change From Baseline in PFT: Forced Expiratory Volume in One Second (FEV1)
LPooled PlaceboCohort 1: BelcesiranCohort 2: Belcesiran
Change From Baseline in PFT: Forced Expiratory Volume in One Second (FEV1)-0.210-0.290 ± 0.2263—
PrimaryChange From Baseline in PFT: FEV1/FVC Ratio

Change in FEV1/FVC ratio from baseline (Day 1) to week 96 is presented. FEV1 is the maximal volume of air exhaled in the first second of a forced expiration from a position of full inspiration. FVC is the maximal volume of air exhaled with maximally forced effort from a maximal inspiration, that is, VC performed with a maximally forced expiratory effort.

Time frame:
Baseline (Day 1), week 96
Reported as:
Mean · Ratio of FEV1/FVC
Change From Baseline in PFT: FEV1/FVC Ratio
Ratio of FEV1/FVCPooled PlaceboCohort 1: BelcesiranCohort 2: Belcesiran
Change From Baseline in PFT: FEV1/FVC Ratio0.020-0.055 ± 0.0778—
PrimaryChange From Baseline in PFT: Diffusing Capacity of the Lungs for Carbon Monoxide (DLCO)

Change in DLCO from baseline (Day 1) to week 96 is presented. DLCO is a measure of the quantity of carbon monoxide (CO) transferred per minute from alveolar gas to red blood cells (specifically hemoglobin) in pulmonary capillaries. It is expressed as millimoles per minute per kilopascal (mmol/min/kPa).

Time frame:
Baseline (Day 1), week 96
Reported as:
Mean · mmol/min/kPa
Change From Baseline in PFT: Diffusing Capacity of the Lungs for Carbon Monoxide (DLCO)
mmol/min/kPaPooled PlaceboCohort 1: BelcesiranCohort 2: Belcesiran
Change From Baseline in PFT: Diffusing Capacity of the Lungs for Carbon Monoxide (DLCO)-1.89497-1.01110 ± 0.146774—
PrimaryChange From Baseline in 12 -Lead Electrochardiograms (ECGs): Mean Heart Rate

Change from baseline (Day 1) to week 96 in mean heart rate is presented.

Time frame:
Baseline (Day 1), week 96
Reported as:
Mean · beats per minute
Change From Baseline in 12 -Lead Electrochardiograms (ECGs): Mean Heart Rate
beats per minutePooled PlaceboCohort 1: BelcesiranCohort 2: Belcesiran
Change From Baseline in 12 -Lead Electrochardiograms (ECGs): Mean Heart Rate-10.01.0—
PrimaryChange From Baseline in 12 -Lead ECGs: Mean Ventricular Rate

Change from baseline (Day 1) to week 96 in mean ventricular rate is presented.

Time frame:
Baseline (Day 1), week 96
Reported as:
Mean · beats per minute
Change From Baseline in 12 -Lead ECGs: Mean Ventricular Rate
beats per minutePooled PlaceboCohort 1: BelcesiranCohort 2: Belcesiran
Change From Baseline in 12 -Lead ECGs: Mean Ventricular Rate-10.01.0—
PrimaryChange From Baseline in 12 -Lead ECGs: PR Interval, QRS Interval, QT Interval, QTcF Interval and RR Interval

Change from baseline (Day 1) to week 96 in PR interval, QRS interval, QT interval, QTcF interval and RR interval is presented.

Time frame:
Baseline (Day 1), week 96
Reported as:
Mean · millisecond (msec)
Change From Baseline in 12 -Lead ECGs: PR Interval, QRS Interval, QT Interval, QTcF Interval and RR Interval
millisecond (msec)Pooled PlaceboCohort 1: BelcesiranCohort 2: Belcesiran
PR interval-4.0——
QRS interval10.021.0—
QT interval26.017.0—
QTcF interval-1.021.0—
RR interval224.0-8.0—
PrimaryNumber of Participants With Physical Examination Findings

Number of participants with physical examination findings at week 96 is presented. The data is presented under categories:a) Normal, b) Abnormal, not clinically significant, c) Abnormal, clinically significant.

Time frame:
At week 96
Reported as:
Count of participants · Participants
Number of Participants With Physical Examination Findings
ParticipantsPooled PlaceboCohort 1: BelcesiranCohort 2: Belcesiran
Normal110
Abnormal, not clinically significant010
Abnormal, clinically significant000
PrimaryChange From Baseline in Vital Signs: Diastolic Blood Pressure and Systolic Blood Pressure

Change from baseline (Day 1) to week 96 in diastolic blood pressure and systolic blood pressure is presented.

Time frame:
Baseline (Day 1), week 96
Reported as:
Mean · millimeters of mercury (mmHg)
Change From Baseline in Vital Signs: Diastolic Blood Pressure and Systolic Blood Pressure
millimeters of mercury (mmHg)Pooled PlaceboCohort 1: BelcesiranCohort 2: Belcesiran
Diastolic blood pressure2.017.0—
Systolic blood pressure13.05.0—
PrimaryChange From Baseline in Vital Signs: Heart Rate

Change from baseline (Day 1) to week 96 in heart rate is presented.

Time frame:
Baseline (Day 1), week 96
Reported as:
Mean · beats per minute
Change From Baseline in Vital Signs: Heart Rate
beats per minutePooled PlaceboCohort 1: BelcesiranCohort 2: Belcesiran
Change From Baseline in Vital Signs: Heart Rate1.021.0—
PrimaryVital Signs: Height at Baseline

Height at baseline is presented.

Time frame:
Baseline (Day 1)
Reported as:
Mean · Centimeter (cm)
Vital Signs: Height at Baseline
Centimeter (cm)Pooled PlaceboCohort 1: BelcesiranCohort 2: Belcesiran
Vital Signs: Height at Baseline178.0 ± 11.07167.8 ± 9.93173.0 ± 13.48
PrimaryChange From Baseline in Vital Signs: Respiratory Rate

Change from baseline (Day 1) to week 96 in respiratory rate is presented.

Time frame:
Baseline (Day 1), week 96
Reported as:
Mean · breaths per minute
Change From Baseline in Vital Signs: Respiratory Rate
breaths per minutePooled PlaceboCohort 1: BelcesiranCohort 2: Belcesiran
Change From Baseline in Vital Signs: Respiratory Rate5.01.0—
PrimaryChange From Baseline in Vital Signs: Temperature

Change from baseline (Day 1) to week 96 in temperature is presented.

Time frame:
Baseline (Day 1), week 96
Reported as:
Mean · Degree celsius
Change From Baseline in Vital Signs: Temperature
Degree celsiusPooled PlaceboCohort 1: BelcesiranCohort 2: Belcesiran
Change From Baseline in Vital Signs: Temperature0.30-0.40—
PrimaryChange From Baseline in Vital Signs: Weight

Change from baseline (Day 1) to week 96 in weight is presented.

Time frame:
Baseline (Day 1), week 96
Reported as:
Mean · kilograms (kg)
Change From Baseline in Vital Signs: Weight
kilograms (kg)Pooled PlaceboCohort 1: BelcesiranCohort 2: Belcesiran
Change From Baseline in Vital Signs: Weight10.700.20—
PrimaryChange in Clinical Laboratory Tests: Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase, Creatine Kinase, Glutamate Dehydrogenase, Lactate Dehydrogenase, Biomarker Creatine Kinase (M30) and Biomarker Creatine Kinase (M65)

Change from baseline (Day 1) to week 96 in alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, creatine kinase, glutamate dehydrogenase, lactate dehydrogenase, biomarker creatine kinase (M30) and biomarker creatine kinase (M65) is presented.

Time frame:
Baseline (Day 1), week 96
Reported as:
Mean · Units per liter (U/L)
Change in Clinical Laboratory Tests: Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase, Creatine Kinase, Glutamate Dehydrogenase, Lactate Dehydrogenase, Biomarker Creatine Kinase (M30) and Biomarker Creatine Kinase (M65)
Units per liter (U/L)Pooled PlaceboCohort 1: BelcesiranCohort 2: Belcesiran
Alanine aminotransferase-8.0-10.5 ± 7.78—
Alkaline phosphatase26.00.0 ± 29.70—
Aspartate aminotransferase-5.0-10.5 ± 6.36—
Creatine kinase-226.0-3.0 ± 8.49—
Glutamate dehydrogenase0.0-4.5 ± 0.71—
Lactate dehydrogenase—0.5 ± 19.09—
Biomarker creatine Kinase (M30)—-149.5 ± 210.01—
Biomarker creatine kinase (M65)—-166.180 ± 329.3703—
PrimaryChange From Baseline in Clinical Laboratory Tests: Albumin, Apolipoprotein A1, Protein, Biomarker Haptoglobin

Change from baseline (Day 1) to week 96 in albumin, apolipoprotein A1, protein and biomarker haptoglobin is presented.

Time frame:
Baseline (Day 1), week 96
Reported as:
Mean · Grams per liter (g/L)
Change From Baseline in Clinical Laboratory Tests: Albumin, Apolipoprotein A1, Protein, Biomarker Haptoglobin
Grams per liter (g/L)Pooled PlaceboCohort 1: BelcesiranCohort 2: Belcesiran
Albumin-1.03.5 ± 0.71—
Apolipoprotein A1-0.0300.180 ± 0.1838—
Protein-2.07.5 ± 7.78—
Biomarker haptoglobin—-0.260—
PrimaryChange From Baseline in Clinical Laboratory Tests: Bilirubin, Creatinine and Direct Bilirubin

Change from baseline (Day 1) to week 96 in bilirubin, creatinine and direct bilirubin is presented.

Time frame:
Baseline (Day 1), week 96
Reported as:
Mean · Micromoles per liter (umol/L)
Change From Baseline in Clinical Laboratory Tests: Bilirubin, Creatinine and Direct Bilirubin
Micromoles per liter (umol/L)Pooled PlaceboCohort 1: BelcesiranCohort 2: Belcesiran
Bilirubin1.7103.420 ± 0.0000—
Creatinine1.768022.5420 ± 19.37755—
Direct bilirubin0.0000.000 ± 0.000—
PrimaryChange From Baseline in Clinical Laboratory Tests: Chloride, Cholesterol, Glucose, Potassium, Sodium, Triglycerides and Urea Nitrogen

Change from baseline (Day 1) to week 96 in chloride, cholesterol, glucose, potassium, sodium, triglycerides and urea nitrogen is presented.

Time frame:
Baseline (Day 1), week 96
Reported as:
Mean · Millimoles per liter (mmol/L)
Change From Baseline in Clinical Laboratory Tests: Chloride, Cholesterol, Glucose, Potassium, Sodium, Triglycerides and Urea Nitrogen
Millimoles per liter (mmol/L)Pooled PlaceboCohort 1: BelcesiranCohort 2: Belcesiran
Chloride-2.0-1.5 ± 6.36—
Cholesterol-0.129500.67340 ± 0.842447—
Glucose0.888000.55500 ± 0.078489—
Potassium-0.600.40 ± 0.283—
Sodium-2.0-0.5 ± 0.71—
Triglycerides-0.011300.44070 ± 0.399515—
Urea nitrogen0.00002.4990 ± 1.00975—
PrimaryChange From Baseline in Clinical Laboratory Tests: Gamma Glutamyl Transferase

Change from baseline (Day 1) to week 96 in gamma glutamyl transferase is presented.

Time frame:
Baseline (Day 1), week 96
Reported as:
Mean · International units per liter (IU/L)
Change From Baseline in Clinical Laboratory Tests: Gamma Glutamyl Transferase
International units per liter (IU/L)Pooled PlaceboCohort 1: BelcesiranCohort 2: Belcesiran
Change From Baseline in Clinical Laboratory Tests: Gamma Glutamyl Transferase-5.0-30.5 ± 24.75—
PrimaryChange From Baseline in Clinical Laboratory Tests: Basophils, Eosinophils, Leucocytes, Lymphocytes, Monocytes, Neutrophils and Platelets

Change from baseline (Day 1) to week 96 in basophils, eosinophils, leucocytes, lymphocytes, monocytes, neutrophils and platelets is presented.

Time frame:
Baseline (Day 1), week 96
Reported as:
Mean · 10^9 cells/liter
Change From Baseline in Clinical Laboratory Tests: Basophils, Eosinophils, Leucocytes, Lymphocytes, Monocytes, Neutrophils and Platelets
10^9 cells/literPooled PlaceboCohort 1: BelcesiranCohort 2: Belcesiran
Basophils-0.0200.000 ± 0.0141—
Eosinophils-0.030-0.020 ± 0.0424—
Leucocytes-1.650-0.600 ± 1.1455—
Lymphocytes0.310-0.130 ± 0.0849—
Monocytes-0.010-0.055 ± 0.4738—
Neutrophils-1.910-0.380 ± 0.5657—
Platelets-39.01.0 ± 16.97—
PrimaryChange From Baseline in Clinical Laboratory Tests: Basophils/Leucocytes

Change from baseline (Day 1) to week 96 in basophils/leucocytes is presented.

Time frame:
Baseline (Day 1), week 96
Reported as:
Mean · Percentage of basophils/leucocytes
Change From Baseline in Clinical Laboratory Tests: Basophils/Leucocytes
Percentage of basophils/leucocytesPooled PlaceboCohort 1: BelcesiranCohort 2: Belcesiran
Change From Baseline in Clinical Laboratory Tests: Basophils/Leucocytes-0.100.10 ± 0.424—
PrimaryChange From Baseline in Clinical Laboratory Tests: Eosinophils/Leucocytes

Change from baseline (Day 1) to week 96 in eosinophils/leucocytes is presented.

Time frame:
Baseline (Day 1), week 96
Reported as:
Mean · Percentage of eosinophils/leucocytes
Change From Baseline in Clinical Laboratory Tests: Eosinophils/Leucocytes
Percentage of eosinophils/leucocytesPooled PlaceboCohort 1: BelcesiranCohort 2: Belcesiran
Change From Baseline in Clinical Laboratory Tests: Eosinophils/Leucocytes0.20-0.05 ± 0.212—
PrimaryChange From Baseline in Clinical Laboratory Tests: Haematocrit

Change from baseline (Day 1) to week 96 in haematocrit is presented.

Time frame:
Baseline (Day 1), week 96
Reported as:
Mean · Percentage of haematocrit
Change From Baseline in Clinical Laboratory Tests: Haematocrit
Percentage of haematocritPooled PlaceboCohort 1: BelcesiranCohort 2: Belcesiran
Change From Baseline in Clinical Laboratory Tests: Haematocrit0.02.5 ± 2.12—
PrimaryChange From Baseline in Clinical Laboratory Tests: Lymphocytes/Leucocytes

Change from baseline (Day 1) to week 96 in lymphocytes/leucocytes is presented.

Time frame:
Baseline (Day 1), week 96
Reported as:
Mean · Percentage of lymphocytes/leucocytes
Change From Baseline in Clinical Laboratory Tests: Lymphocytes/Leucocytes
Percentage of lymphocytes/leucocytesPooled PlaceboCohort 1: BelcesiranCohort 2: Belcesiran
Change From Baseline in Clinical Laboratory Tests: Lymphocytes/Leucocytes17.300.85 ± 4.031—
PrimaryChange From Baseline in Clinical Laboratory Tests: Monocytes/Leucocytes

Change from baseline (Day 1) to week 96 in monocytes/leucocytes is presented.

Time frame:
Baseline (Day 1), week 96
Reported as:
Mean · Percentage of monocytes/leucocytes
Change From Baseline in Clinical Laboratory Tests: Monocytes/Leucocytes
Percentage of monocytes/leucocytesPooled PlaceboCohort 1: BelcesiranCohort 2: Belcesiran
Change From Baseline in Clinical Laboratory Tests: Monocytes/Leucocytes1.20-0.50 ± 6.081—
PrimaryChange From Baseline in Clinical Laboratory Tests: Neutrophils/Leucocytes

Change from baseline (Day 1) to week 96 in neutrophils/leucocytes is presented.

Time frame:
Baseline (Day 1), week 96
Reported as:
Mean · Percentage of neutrophils/leucocytes
Change From Baseline in Clinical Laboratory Tests: Neutrophils/Leucocytes
Percentage of neutrophils/leucocytesPooled PlaceboCohort 1: BelcesiranCohort 2: Belcesiran
Change From Baseline in Clinical Laboratory Tests: Neutrophils/Leucocytes-18.70-0.40 ± 1.838—
PrimaryChange From Baseline in Clinical Laboratory Tests: Reticulocytes/Erythrocytes

Change from baseline (Day 1) to week 96 in reticulocytes/erythrocytes is presented.

Time frame:
Baseline (Day 1), week 96
Reported as:
Mean · Percentage of reticulocytes/erythrocytes
Change From Baseline in Clinical Laboratory Tests: Reticulocytes/Erythrocytes
Percentage of reticulocytes/erythrocytesPooled PlaceboCohort 1: BelcesiranCohort 2: Belcesiran
Change From Baseline in Clinical Laboratory Tests: Reticulocytes/Erythrocytes-0.800.30 ± 0.141—
PrimaryChange From Baseline in Clinical Laboratory Tests: Erythrocyte Mean Corpuscular Haemoglobin Concentration and Haemoglobin

Change from baseline (Day 1) to week 96 in erythrocyte mean corpuscular haemoglobin concentration and haemoglobin is presented.

Time frame:
Baseline (Day 1), week 96
Reported as:
Mean · g/L
Change From Baseline in Clinical Laboratory Tests: Erythrocyte Mean Corpuscular Haemoglobin Concentration and Haemoglobin
g/LPooled PlaceboCohort 1: BelcesiranCohort 2: Belcesiran
Erythrocyte mean corpuscular haemoglobin concentration-10.00.0 ± 0.0—
Haemoglobin-6.09.0 ± 4.24—
PrimaryChange From Baseline in Clinical Laboratory Tests: Erythrocyte Mean Corpuscular Haemoglobin

Change from baseline (Day 1) to week 96 in erythrocyte mean corpuscular haemoglobin is presented.

Time frame:
Baseline (Day 1), week 96
Reported as:
Mean · picograms (pg)
Change From Baseline in Clinical Laboratory Tests: Erythrocyte Mean Corpuscular Haemoglobin
picograms (pg)Pooled PlaceboCohort 1: BelcesiranCohort 2: Belcesiran
Change From Baseline in Clinical Laboratory Tests: Erythrocyte Mean Corpuscular Haemoglobin-1.00.5 ± 0.71—
PrimaryChange From Baseline in Clinical Laboratory Tests: Erythrocyte Mean Corpuscular Volume

Change from baseline (Day 1) to week 96 in erythrocyte mean corpuscular volume is presented.

Time frame:
Baseline (Day 1), week 96
Reported as:
Mean · femtoliter (fL)
Change From Baseline in Clinical Laboratory Tests: Erythrocyte Mean Corpuscular Volume
femtoliter (fL)Pooled PlaceboCohort 1: BelcesiranCohort 2: Belcesiran
Change From Baseline in Clinical Laboratory Tests: Erythrocyte Mean Corpuscular Volume2.02.5 ± 0.71—
PrimaryChange From Baseline in Clinical Laboratory Tests: Erythrocytes

Change from baseline (Day 1) to week 96 in erythrocytes is presented.

Time frame:
Baseline (Day 1), week 96
Reported as:
Mean · 10^12 cells/liter
Change From Baseline in Clinical Laboratory Tests: Erythrocytes
10^12 cells/literPooled PlaceboCohort 1: BelcesiranCohort 2: Belcesiran
Change From Baseline in Clinical Laboratory Tests: Erythrocytes-0.100.20 ± 0.141—
PrimaryChange From Baseline in Clinical Laboratory Tests: Specific Gravity

Change from baseline (Day 1) to week 96 in specific gravity is reported.

Time frame:
Baseline (Day 1), week 96
Reported as:
Mean · Ratio
Change From Baseline in Clinical Laboratory Tests: Specific Gravity
RatioPooled PlaceboCohort 1: BelcesiranCohort 2: Belcesiran
Change From Baseline in Clinical Laboratory Tests: Specific Gravity-0.00500.0025 ± 0.01061—
PrimaryChange From Baseline in Clinical Laboratory Tests: Urine Erythrocytes and Urine Leucocytes

Change from baseline (Day 1) to week 96 in urine erythrocytes and urine leucocytes is presented.

Time frame:
Baseline (Day 1), week 96
Reported as:
Mean · per high power field (/HPF)
Change From Baseline in Clinical Laboratory Tests: Urine Erythrocytes and Urine Leucocytes
per high power field (/HPF)Pooled PlaceboCohort 1: BelcesiranCohort 2: Belcesiran
Urine erythrocytes—3.0—
Urine leucocytes—0.0—
PrimaryChange From Baseline in Clinical Laboratory Tests: Potential of Hydrogen (pH)

Change from baseline (Day 1) to week 96 in pH is presented.

Time frame:
Baseline (Day 1), week 96
Reported as:
Mean · pH
Change From Baseline in Clinical Laboratory Tests: Potential of Hydrogen (pH)
pHPooled PlaceboCohort 1: BelcesiranCohort 2: Belcesiran
Change From Baseline in Clinical Laboratory Tests: Potential of Hydrogen (pH)0.00-0.75 ± 1.061—
PrimaryChange From Baseline in Clinical Laboratory Tests: Activated Partial Thromboplastin Time and Prothrombin Time

Change from baseline (Day 1) to week 96 in activated partial thromboplastin time and prothrombin time is presented.

Time frame:
Baseline (Day 1), week 96
Reported as:
Mean · seconds (sec)
Change From Baseline in Clinical Laboratory Tests: Activated Partial Thromboplastin Time and Prothrombin Time
seconds (sec)Pooled PlaceboCohort 1: BelcesiranCohort 2: Belcesiran
Activated partial thromboplastin time0.401.55 ± 2.333—
Prothrombin time-0.500.40 ± 0.990—
PrimaryChange From Baseline in Clinical Laboratory Tests: Prothrombin International Normalized Ratio

Change from baseline (Day 1) to week 96 in prothrombin international normalized ratio is presented.

Time frame:
Baseline (Day 1), week 96
Reported as:
Mean · Ratio
Change From Baseline in Clinical Laboratory Tests: Prothrombin International Normalized Ratio
RatioPooled PlaceboCohort 1: BelcesiranCohort 2: Belcesiran
Change From Baseline in Clinical Laboratory Tests: Prothrombin International Normalized Ratio0.000.00 ± 0.141—
PrimaryChange in Clinical Laboratory Tests: Alpha Fetoprotein, Biomarker Hyaluronic Acid, Biomarker Matrix Metalloproteinase 9, Biomarker Procollagen 3 N-Terminal Propeptide, Biomarker Tissue Inhibitor of Metalloproteinase 1, Complement C3a and Complement C5a

Change from baseline (Day 1) to week 96 in alpha fetoprotein, biomarker hyaluronic acid, biomarker matrix metalloproteinase 9, biomarker procollagen 3 N-Terminal propeptide, biomarker tissue inhibitor of metalloproteinase 1, complement C3a and complement C5a is presented.

Time frame:
Baseline (Day 1), week 96
Reported as:
Mean · nanograms per milliter (ng/mL)
Change in Clinical Laboratory Tests: Alpha Fetoprotein, Biomarker Hyaluronic Acid, Biomarker Matrix Metalloproteinase 9, Biomarker Procollagen 3 N-Terminal Propeptide, Biomarker Tissue Inhibitor of Metalloproteinase 1, Complement C3a and Complement C5a
nanograms per milliter (ng/mL)Pooled PlaceboCohort 1: BelcesiranCohort 2: Belcesiran
Alpha fetoprotein0.302.90 ± 2.687—
Biomarker hyaluronic acid—137.305 ± 310.3704—
Biomarker matrix metalloproteinase 9—-193.65 ± 239.356—
Biomarker procollagen 3 N-terminal propeptide—-0.655 ± 0.5020—
Biomarker tissue inhibitor of metalloproteinase 1—-83.25 ± 8.980—
Complement C3a139.70-5.60 ± 5.657—
Complement C5a1.890-1.785 ± 0.6152—
PrimaryChange From Baseline in Clinical Laboratory Tests: C-Reactive Protein

Change from baseline (Day 1) to week 96 in C-reactive protein is presented.

Time frame:
Baseline (Day 1), week 96
Reported as:
Mean · mg/L
Change From Baseline in Clinical Laboratory Tests: C-Reactive Protein
mg/LPooled PlaceboCohort 1: BelcesiranCohort 2: Belcesiran
Change From Baseline in Clinical Laboratory Tests: C-Reactive Protein4.30-0.30 ± 0.849—
PrimaryChange From Baseline in Clinical Laboratory Tests: Complement Bb

Change from baseline (Day 1) to week 96 in complement Bb is presented.

Time frame:
Baseline (Day 1), week 96
Reported as:
Mean · microgram per milliliter (ug/mL)
Change From Baseline in Clinical Laboratory Tests: Complement Bb
microgram per milliliter (ug/mL)Pooled PlaceboCohort 1: BelcesiranCohort 2: Belcesiran
Change From Baseline in Clinical Laboratory Tests: Complement Bb0.2400.325 ± 0.2616—
PrimaryChange From Baseline in Clinical Laboratory Tests: Complement Total (CH50)

Change from baseline (Day 1) to week 96 in CH50 is presented.

Time frame:
Baseline (Day 1), week 96
Reported as:
Mean · equivalent unit per milliliter (U Eq/mL)
Change From Baseline in Clinical Laboratory Tests: Complement Total (CH50)
equivalent unit per milliliter (U Eq/mL)Pooled PlaceboCohort 1: BelcesiranCohort 2: Belcesiran
Change From Baseline in Clinical Laboratory Tests: Complement Total (CH50)6.530-46.900 ± 40.1071—
PrimaryCohort 1: Change From Baseline in Serum Alpha-1 Antitrypsin (AAT) Protein Concentrations

Change from baseline (Day 1) to week 24 in serum AAT protein concentrations in Cohort 1 is presented.

Time frame:
Baseline (Day 1), week 24
Reported as:
Mean · g/L
Cohort 1: Change From Baseline in Serum Alpha-1 Antitrypsin (AAT) Protein Concentrations
g/LCohort 1: Belcesiran
Cohort 1: Change From Baseline in Serum Alpha-1 Antitrypsin (AAT) Protein Concentrations-0.30 ± 0.120
PrimaryCohort 2: Change From Baseline in Serum AAT Protein Concentrations

Change from baseline (Day 1) to week 48 in serum AAT protein concentrations in Cohort 2 is presented.

Time frame:
Baseline (Day 1), week 48
Reported as:
Mean · g/L
Cohort 2: Change From Baseline in Serum AAT Protein Concentrations
g/LCohort 2: Belcesiran
Cohort 2: Change From Baseline in Serum AAT Protein Concentrations-0.50 ± 0.094
SecondaryChange From Baseline in Liver Fibrosis Ishak Score

Change from Baseline up until week 48 in liver fibrosis based on Ishak score is presented. The Ishak staging system for liver fibrosis is a 1995 update to the algorithm initially developed by De Groote et al. Ishak scores range from 0 (no fibrosis) to 6 (cirrhosis) which are as follows: 0-no fibrosis, 1-fibrous expansion of some portal areas, with or without short fibrous septa, 2-Fibrous expansion of most portal areas, with or without short fibrous septa, 3-Fibrous expansion of most portal areas with occasional portal-to-portal bridging, 4-Fibrous expansion of portal areas with marked bridging (portal to portal as well as portal to central), 5-Marked bridging (portal-portal and/or portal-central) with occasional nodules (incomplete cirrhosis), 6-Cirrhosis, probable or definite.

Time frame:
Baseline (Day 1), week 48
Reported as:
Mean · unit on a score
Change From Baseline in Liver Fibrosis Ishak Score
unit on a scorePooled PlaceboCohort 1: BelcesiranCohort 2: Belcesiran
Change From Baseline in Liver Fibrosis Ishak Score1.0—-1.0 ± 0.00

Adverse events

Collected over Up to 2.6 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pooled Placebo0/5 (0%)0/5 (0%)5/5 (100%)
Cohort 1: Belcesiran0/5 (0%)2/5 (40%)5/5 (100%)
Cohort 2: Belcesiran0/6 (0%)2/6 (33.3%)5/6 (83.3%)
Most frequent serious events
Most frequent serious events
EventPooled PlaceboCohort 1: BelcesiranCohort 2: Belcesiran
Atrial fibrillationCardiac disorders0/51/50/6
PneumoniaInfections and infestations0/51/50/6
HyperglycaemiaMetabolism and nutrition disorders0/51/50/6
Hepatic encephalopathyNervous system disorders0/51/50/6
DepressionPsychiatric disorders0/51/50/6
Acute myocardial infarctionCardiac disorders0/50/51/6
ErysipelasInfections and infestations0/50/51/6
Viral infectionInfections and infestations0/50/51/6
Hepatic function abnormalHepatobiliary disorders0/50/51/6
Pulmonary function test decreasedInvestigations0/50/51/6
Most frequent other events
Showing 10 of 97
Most frequent other events
EventPooled PlaceboCohort 1: BelcesiranCohort 2: Belcesiran
Crystal urine presentInvestigations1/52/50/6
HeadacheNervous system disorders0/52/50/6
COVID-19Infections and infestations0/51/52/6
Upper respiratory tract infectionInfections and infestations0/51/52/6
CoughRespiratory, thoracic and mediastinal disorders1/51/52/6
ThrombocytopeniaBlood and lymphatic system disorders1/50/52/6
BronchitisInfections and infestations0/51/51/6
PneumoniaInfections and infestations0/51/50/6
Asymptomatic bacteriuriaInfections and infestations0/51/50/6
CystitisInfections and infestations0/51/50/6

Baseline characteristics

Safety Population is defined as all participants randomly assigned to study intervention who had received at least 1 dose of the study drug (belcesiran or placebo).

Age, Continuous
Age, Continuous(Years)Pooled PlaceboCohort 1: BelcesiranCohort 2: BelcesiranTotal
Mean40.2 ± 17.3157.2 ± 10.1852.5 ± 11.8650.1 ± 14.36
Sex: Female, Male
Sex: Female, Male(Participants)Pooled PlaceboCohort 1: BelcesiranCohort 2: BelcesiranTotal
Female1326
Male42410
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Pooled PlaceboCohort 1: BelcesiranCohort 2: BelcesiranTotal
White55616
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Pooled PlaceboCohort 1: BelcesiranCohort 2: BelcesiranTotal
Not Hispanic or Latino55616
08

Study locations

23 sites
  • University of California - San Diego
    La Jolla, California 92093, United States
  • University of Florida
    Gainesville, Florida 32611, United States
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
  • St Vincent's Hospital Melbourne
    Melbourne, Australia
  • Medizinische Universitaet Innsbruck
    Innsbruck, Austria
  • Universitaire Ziekenhuizen Leuven
    Leuven, Belgium
  • Centre Hospitalier de l'Universite de Montreal (CHUM)
    Montreal, Quebec, Canada
  • CHU Bordeaux - Hopital Haut-Leveque - Centre François Magendie
    Pessac, France
  • Universitaetsklinikum Aachen, AoeR
    Aachen, Germany
  • Universitaetsklinikum Schleswig-Holstein Campus Kiel
    Kiel, Germany
  • Beaumont Hospital
    Dublin, Ireland
  • Leiden University Medical Center
    Leiden, Netherlands
  • Auckland Clinical Studies
    Grafton, Auckland 1010, New Zealand
  • Waikato Hospital
    Hamilton, New Zealand
  • Hospital da Senhora da Oliveira - Guimaraes
    Creixomil, Portugal
  • Centro Hospitalar Universitario de Sao Joao
    Porto, Portugal
  • Centro Hospitalar de Trás-os-Montes e Alto Douro, EPE
    Vila Real, Portugal
  • Hospital Universitario Marques de Valdecilla Santander
    Santander, Cantabria, Spain
  • Hospital Universitario La Paz
    Madrid, Spain
  • CTC Clinical Trial Consultants AB Uppsala
    Uppsala, Sweden
  • Addenbrooke's Hospital, Cambridge University
    Cambridge, United Kingdom
  • Leeds Teaching Hospitals NHS Trust
    Leeds, United Kingdom
  • Royal Free London NHS Foundation Trust, Royal Free Hospital
    London, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2021 to primary completion in Dec 2023, 33 months.

Results were first posted in Dec 2024, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 27, 2021
First posted
Feb 21, 2021
StartActual
Feb 12, 2021
Primary completionActual
Dec 8, 2023
CompletionActual
May 29, 2024
Results first posted
Dec 31, 2024
Last update
Apr 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04764448
Responsible party
Sponsor
First posted
Feb 21, 2021
Start date
Feb 12, 2021
Primary completion
Dec 8, 2023
Completion
May 29, 2024
Results posted
Dec 31, 2024
Last update
Apr 7, 2026

Study contacts

Thomas Bowman, MD
study director · Dicerna Pharmaceuticals / Novo Nordisk

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Belcesiran

Start the discussion